Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of $162.80 million. The enterprise value is $147.92 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SGMO has 301.71 million shares outstanding. The number of shares has increased by 20.61% in one year.
Current Share Class | 301.71M |
Shares Outstanding | 301.71M |
Shares Change (YoY) | +20.61% |
Shares Change (QoQ) | +16.65% |
Owned by Insiders (%) | 1.15% |
Owned by Institutions (%) | 17.92% |
Float | 294.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.48 |
Forward PS | 2.22 |
PB Ratio | 7.51 |
P/TBV Ratio | 8.31 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.81 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.20.
Current Ratio | 1.05 |
Quick Ratio | 0.91 |
Debt / Equity | 1.20 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.19 |
Financial Efficiency
Return on equity (ROE) is -292.47% and return on invested capital (ROIC) is -81.82%.
Return on Equity (ROE) | -292.47% |
Return on Assets (ROA) | -41.15% |
Return on Invested Capital (ROIC) | -81.82% |
Return on Capital Employed (ROCE) | -125.74% |
Revenue Per Employee | $446,481 |
Profits Per Employee | -$345,940 |
Employee Count | 183 |
Asset Turnover | 0.86 |
Inventory Turnover | n/a |
Taxes
Income Tax | -193,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.05% in the last 52 weeks. The beta is 1.19, so SGMO's price volatility has been higher than the market average.
Beta (5Y) | 1.19 |
52-Week Price Change | -51.05% |
50-Day Moving Average | 0.52 |
200-Day Moving Average | 1.09 |
Relative Strength Index (RSI) | 52.87 |
Average Volume (20 Days) | 7,230,824 |
Short Selling Information
The latest short interest is 13.66 million, so 4.53% of the outstanding shares have been sold short.
Short Interest | 13.66M |
Short Previous Month | 23.36M |
Short % of Shares Out | 4.53% |
Short % of Float | 4.63% |
Short Ratio (days to cover) | 2.43 |
Income Statement
In the last 12 months, SGMO had revenue of $81.71 million and -$63.31 million in losses. Loss per share was -$0.28.
Revenue | 81.71M |
Gross Profit | -22.79M |
Operating Income | -62.74M |
Pretax Income | -248.51M |
Net Income | -63.31M |
EBITDA | -58.27M |
EBIT | -62.74M |
Loss Per Share | -$0.28 |
Full Income Statement Balance Sheet
The company has $38.34 million in cash and $23.46 million in debt, giving a net cash position of $14.88 million or $0.05 per share.
Cash & Cash Equivalents | 38.34M |
Total Debt | 23.46M |
Net Cash | 14.88M |
Net Cash Per Share | $0.05 |
Equity (Book Value) | 19.60M |
Book Value Per Share | 0.07 |
Working Capital | 2.23M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$35.90 million and capital expenditures -$291,000, giving a free cash flow of -$36.19 million.
Operating Cash Flow | -35.90M |
Capital Expenditures | -291,000 |
Free Cash Flow | -36.19M |
FCF Per Share | -$0.12 |
Full Cash Flow Statement Margins
Gross margin is -27.89%, with operating and profit margins of -76.79% and -77.48%.
Gross Margin | -27.89% |
Operating Margin | -76.79% |
Pretax Margin | -77.72% |
Profit Margin | -77.48% |
EBITDA Margin | -71.32% |
EBIT Margin | -76.79% |
FCF Margin | n/a |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -20.61% |
Shareholder Yield | -20.61% |
Earnings Yield | -38.89% |
FCF Yield | -22.23% |
Analyst Forecast
The average price target for SGMO is $4.50, which is 733.95% higher than the current price. The consensus rating is "Buy".
Price Target | $4.50 |
Price Target Difference | 733.95% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 37.50% |
EPS Growth Forecast (5Y) | -24.96% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -21.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -21.84 |
Piotroski F-Score | 4 |